ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
04 Januar 2024 - 1:50PM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of patients with renal and inflammatory
diseases who have unmet medical needs, announces that Noble Capital
Markets has initiated company-sponsored equity research coverage.
To obtain a copy of the full report authored by Noble Capital
Markets’ Senior Research Analyst Robert LeBoyer, as well as news
and advanced market data on ZyVersa Therapeutics, please go to
Channelchek.com.
About ZyVersa Therapeutics,
Inc.
ZyVersa is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs. Our focus is on
patients with renal or inflammatory diseases who have significant
unmet medical needs. Our development pipeline includes clinical
stage Cholesterol Efflux MediatorTM VAR 200 in development to
alleviate damaging accumulation of cholesterol and lipids in the
kidneys’ filtration system. The lead indication is treatment of
rare kidney disease, focal segmental glomerulosclerosis. VAR 200
has potential to treat other kidney diseases, including Alport
syndrome and diabetic kidney disease. ZyVersa’s pipeline also
includes proprietary inflammasome ASC inhibitor IC 100 that blocks
initiation and perpetuation of damaging inflammation associated
with a multitude of inflammatory diseases. IC 100 has potential to
treat many different CNS and other inflammatory diseases. For more
information, please visit www.zyversa.com.
About Noble Capital Markets
Noble Capital Markets, Inc. was incorporated in
1984 as a full-service SEC / FINRA registered broker-dealer,
dedicated exclusively to serving underfollowed small/microcap
companies through investment banking, wealth management, trading
& execution, and equity research activities. Over the past 37
years, Noble has raised billions of dollars for these companies and
published more than 45,000 equity research reports. For more
information, please visit www.noblecapitalmarkets.com or email:
contact@noblecapitalmarkets.com.
About Channelchek
Channelchek (.com) is a comprehensive
investor-centric portal - featuring more than 6,000 emerging growth
companies - that provides advanced market data, independent
research, balanced news, video webcasts, exclusive c-suite
interviews, and access to virtual road shows. The site is available
to the public at every level without cost or obligation. Research
on Channelchek is provided by Noble Capital Markets, Inc., an SEC /
FINRA registered broker-dealer since 1984. For more information, go
to www.channelchek.com or email: contact@channelchek.com.
Cautionary Statement Regarding
Forward-Looking Statements
Certain statements contained in this press release
regarding matters that are not historical facts, are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and the Private
Securities Litigation Reform Act of 1995. These include statements
regarding management’s intentions, plans, beliefs, expectations, or
forecasts for the future, and, therefore, you are cautioned not to
place undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional financing. A
discussion of these and other factors, including risks and
uncertainties with respect to ZyVersa, is set forth in ZyVersa’s
filings with the Securities and Exchange Commission, including
ZyVersa’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q.
New factors emerge from time-to-time, and it is not
possible for ZyVersa to predict all such factors, nor can ZyVersa
assess the impact of each such factor on the business or the extent
to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any
forward-looking statements. Forward-looking statements included in
this press release are based on information available to ZyVersa as
of the date of this press release. ZyVersa disclaims any obligation
to update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to
sell, or the solicitation of an offer to buy, any securities.
Corporate and IR ContactKaren
CashmereChief Commercial
Officerkcashmere@zyversa.com786-251-9641
Media ContactsCasey
McDonaldcmcdonald@tiberend.com646-577-8520
Dave
SchemeliaDschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
Von Jun 2023 bis Jun 2024